The estimated Net Worth of Christopher Moxham is at least $275 ezer dollars as of 10 August 2021. Christopher Moxham owns over 51,785 units of Fulcrum Therapeutics Inc stock worth over $274,978 and over the last 4 years Christopher sold FULC stock worth over $0.
Christopher has made over 1 trades of the Fulcrum Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Christopher exercised 51,785 units of FULC stock worth $405,994 on 10 August 2021.
The largest trade Christopher's ever made was exercising 51,785 units of Fulcrum Therapeutics Inc stock on 10 August 2021 worth over $405,994. On average, Christopher trades about 25,893 units every 0 days since 2021. As of 10 August 2021 Christopher still owns at least 31,071 units of Fulcrum Therapeutics Inc stock.
You can see the complete history of Christopher Moxham stock trades at the bottom of the page.
Christopher's mailing address filed with the SEC is C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139.
Over the last 5 years, insiders at Fulcrum Therapeutics Inc have traded over $1,450,584 worth of Fulcrum Therapeutics Inc stock and bought 5,263,802 units worth $50,137,344 . The most active insiders traders include Sanofi, Plc Gsk és Capital Management, L.P.Ra .... On average, Fulcrum Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $868,035. The most recent stock trade was executed by Alex Sapir on 3 July 2024, trading 150,000 units of FULC stock currently worth $490,500.
what if we could regulate genes, not just discover them? what if we could treat disease at their genetic source? what if we could integrate multiple disciplines to develop breakthrough medicines? what if you could be a part of a passionate team committed to the patients we serve? we can. we will. we are. join us. we are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. a fulcrum is defined as the point on which a lever rests, balances and pivots. fulcrum therapeutics is intervening in gene regulatory mechanisms to unlock the information contained in the human genome. the fulcrum product engine is dedicated to bringing balance to the genetic on and off switches in disease. our approach the sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. the fulcrum product eng
Fulcrum Therapeutics Inc executives and other stock owners filed with the SEC include: